Stryker
Prezzo: 312.20Società e modello di business
Stryker Corporation is a leading medical technology company that develops and manufactures a range of products in the healthcare sector. Its core offerings include surgical equipment, orthopedic implants, neurotechnology, and spine products. Major business segments consist of Orthopedics, MedSurg, and Neurotechnology & Spine. The primary revenue sources are derived from sales of surgical instruments, implants, and related services.
Profilo di investimento
The investment profile of Stryker is more aligned with value investors, given its current dividend yield and established market presence. However, recent revenue declines and earnings surprises may indicate challenges in growth potential. The stock may appeal to those seeking stability rather than aggressive growth.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 8.73 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -16.1% ↓
- Sorpresa EPS
- -12.8% peggio del previsto
- Volatilità 20g
- 1.8% stabile
- Rendimento dividendo
- 1.4% moderato ultima data ex-dividendo: 2026-06-30
Impatto della previsione
negativoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-05-10 02:45 | Mantieni | Vendi | scenario_deterioration |
| 2026-05-08 15:19 | — | Mantieni | Weak fundamentals and negative momentum indicate high risk. |
| 2026-05-08 06:38 | Mantieni | Mantieni | Компания Stryker демонстрирует значительное снижение выручки и негативные тренды на фондовом рынке, что указывает на высокие риски для инвесторов. Учитывая текущие показатели и негативные прогнозы, рекомендуется рассмотр |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-05 09:16 | Leerink Partners | Target abbassato | — → 407 | 301.21 |
| 2026-05-04 13:39 | Truist Financial | Target abbassato | 380 → 330 | 293.44 |
| 2026-05-04 09:27 | Barclays | Target abbassato | 469 → 394 | 294.73 |
Ancora nulla